Biological Therapy with Oncolytic Herpesvirus
Oncolytic virus therapy refers to the biological therapy of tumors, using live viruses with relative tumor selectivity. Replication-restricted virus strains have been genetically engineered, which replicate selectively within tumor cells. Examples include replication-competent mutants of herpes virus, adenovirus, vesicular stomatitis virus, reovirus, and measles virus (2, 17, 37, Martuza, 2000; 56, 63). In particular, replication-competent recombinant HSV strains may offer distinct advantages in oncolytic therapy of epithelial tumors: (a) HSV is highly infectious to tumors of epithelial origin, resulting in high efficacy (70); (b) there is considerable redundancy in HSV receptors, which makes the loss of HSV receptors by tumors due to mutations less likely; (c) antiherpetic drugs are commercially available, which may be used clinically to control undesired side effects, should local or systemic spread of the virus occur; and (d) because of its large genome, HSV offers ample packaging opportunities – up to 30 kb – without affecting viral replication in cancer cells.
KeywordsVascular Endothelial Growth Factor Ovarian Carcinoma Herpes Simplex Virus Type Vascular Endothelial Growth Factor Level Epithelial Ovarian Carcinoma
Unable to display preview. Download preview PDF.